{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:08Z","timestamp":1786982768392,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T00:00:00Z","timestamp":1487116800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Alexza Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s40262-017-0512-x","type":"journal-article","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T08:36:31Z","timestamp":1487147791000},"page":"1207-1217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical Trial Simulations and Pharmacometric Analysis in Pediatrics: Application to Inhaled Loxapine in Children and Adolescents"],"prefix":"10.1007","volume":"56","author":[{"given":"Min","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Selim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rabinovich-Guilatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James V.","family":"Cassella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Vinks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,15]]},"reference":[{"key":"512_CR1","unstructured":"Adasuve [package insert]. Horsham (PA). USA: Teva Pharmaceuticals; 2013."},{"issue":"3","key":"512_CR2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2165\/00003495-197815030-00002","volume":"15","author":"RC Heel","year":"1978","unstructured":"Heel RC, Brogden RN, Speight TM, Avery GS. Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent. Drugs. 1978;15(3):198\u2013217.","journal-title":"Drugs"},{"issue":"1\u20132","key":"512_CR3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijpharm.2010.10.030","volume":"403","author":"K Dinh","year":"2011","unstructured":"Dinh K, Myers DJ, Glazer M, et al. In vitro aerosol characterization of Staccato\u00ae Loxapine. Int J Pharm. 2011;403(1\u20132):101\u20138.","journal-title":"Int J Pharm"},{"issue":"10","key":"512_CR4","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.4088\/JCP.10m06011yel","volume":"72","author":"MH Allen","year":"2011","unstructured":"Allen MH, Feifel D, Lesem MD, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(10):1313\u201321.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"512_CR5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1192\/bjp.bp.110.081513","volume":"198","author":"MD Lesem","year":"2011","unstructured":"Lesem MD, Tran-Johnson TK, Riesenberg RA, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry. 2011;198(1):51\u20138.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"512_CR6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1399-5618.2011.00975.x","volume":"14","author":"J Kwentus","year":"2012","unstructured":"Kwentus J, Riesenberg RA, Marandi M, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012;14(1):31\u201340.","journal-title":"Bipolar Disord"},{"issue":"9","key":"512_CR7","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/00004583-199709000-00008","volume":"36","author":"B Geller","year":"1997","unstructured":"Geller B, Luby J. Child and adolescent bipolar disorder: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry. 1997;36(9):1168\u201376.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"512_CR8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/BF02190734","volume":"245","author":"H Hafner","year":"1995","unstructured":"Hafner H, Nowotny B. Epidemiology of early-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci. 1995;245(2):80\u201392.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"2","key":"512_CR9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/cap.2014.0003","volume":"25","author":"JA Hellings","year":"2015","unstructured":"Hellings JA, Reed G, Cain SE, et al. Loxapine add-on for adolescents and adults with autism spectrum disorders and irritability. J Child Adolesc Psychopharmacol. 2015;25(2):150\u20139.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"512_CR10","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1089\/cap.2006.16.639","volume":"16","author":"SP Reinblatt","year":"2006","unstructured":"Reinblatt SP, Abanilla PK, Jummani R, Coffey B. Loxapine treatment in an autistic child with aggressive behavior: therapeutic challenges. J Child Adolesc Psychopharmacol. 2006;16(5):639\u201343.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"512_CR11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/0091270009347866","volume":"50","author":"DA Spyker","year":"2010","unstructured":"Spyker DA, Munzar P, Cassella JV. Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J Clin Pharmacol. 2010;50(2):169\u201379.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"512_CR12","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/bdd.768","volume":"32","author":"JP Luo","year":"2011","unstructured":"Luo JP, Vashishtha SC, Hawes EM, et al. In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos. 2011;32(7):398\u2013407.","journal-title":"Biopharm Drug Dispos"},{"issue":"4","key":"512_CR13","first-page":"177","volume":"31","author":"KK Midha","year":"1993","unstructured":"Midha KK, Hubbard JW, McKay G, et al. The role of metabolites in a bioequivalence study 1: loxapine, 7-hydroxyloxapine and 8-hydroxyloxapine. Int J Clin Pharmacol Ther Toxicol. 1993;31(4):177\u201383.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"issue":"5","key":"512_CR14","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/FTD.0000000000000048","volume":"36","author":"LH Takahashi","year":"2014","unstructured":"Takahashi LH, Huie K, Spyker DA, et al. Effect of smoking on the pharmacokinetics of inhaled loxapine. Ther Drug Monit. 2014;36(5):618\u201323.","journal-title":"Ther Drug Monit"},{"issue":"12","key":"512_CR15","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.4155\/bio.10.156","volume":"2","author":"JS Zimmer","year":"2010","unstructured":"Zimmer JS, Needham SR, Christianson CD, et al. Validation of HPLC-MS\/MS methods for analysis of loxapine, amoxapine, 7-OH-loxapine, 8-OH-loxapine and loxapine N-oxide in human plasma. Bioanalysis. 2010;2(12):1989\u20132000.","journal-title":"Bioanalysis"},{"key":"512_CR16","volume-title":"NONMEM user\u2019s guide (1989\u20132009)","author":"S Beal","year":"2009","unstructured":"Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM user\u2019s guide (1989\u20132009). Ellicott City (MO): ICON Development Solutions; 2009."},{"issue":"3","key":"512_CR17","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11(3):558\u201369.","journal-title":"AAPS J"},{"issue":"1","key":"512_CR18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1999","unstructured":"Jonsson EN, Karlsson MO. Xpose: an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58(1):51\u201364.","journal-title":"Comput Methods Programs Biomed"},{"issue":"4","key":"512_CR19","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/bcp.12851","volume":"81","author":"M Dong","year":"2016","unstructured":"Dong M, McGann PT, Mizuno T, et al. Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia. Br J Clin Pharmacol. 2016;81(4):742\u201352.","journal-title":"Br J Clin Pharmacol"},{"key":"512_CR20","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013;2:e38.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"512_CR21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/FTD.0b013e31824d6a4e","volume":"34","author":"B Punyawudho","year":"2012","unstructured":"Punyawudho B, Ramsay ER, Brundage RC, et al. Population pharmacokinetics of carbamazepine in elderly patients. Ther Drug Monit. 2012;34(2):176\u201381.","journal-title":"Ther Drug Monit"},{"key":"512_CR22","unstructured":"Holford N. The visual predictive check: superiority to standard diagnostic (Rorschach) plots [abstract no. 738]. Annual Meeting of the Population Approach Group in Europe; 16\u201317 Jun 2005; Pamplona, Spain."},{"key":"512_CR23","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1038\/psp.2013.24","volume":"2","author":"RJ Keizer","year":"2013","unstructured":"Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol. 2013;2:e50.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"512_CR24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1460-9592.2011.03536.x","volume":"21","author":"BJ Anderson","year":"2011","unstructured":"Anderson BJ, Holford NH. Tips and traps analyzing pediatric PK data. Paediatr Anaesth. 2011;21(3):222\u201337.","journal-title":"Paediatr Anaesth"},{"issue":"3","key":"512_CR25","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/cpt.169","volume":"98","author":"AA Vinks","year":"2015","unstructured":"Vinks AA, Emoto C, Fukuda T. Modeling and simulation in pediatric drug therapy: application of pharmacometrics to define the right dose for children. Clin Pharmacol Ther. 2015;98(3):298\u2013308.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"512_CR26","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00431-006-0189-x","volume":"165","author":"BJ Anderson","year":"2006","unstructured":"Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr. 2006;165(12):819\u201329.","journal-title":"Eur J Pediatr"},{"key":"512_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0436-x","author":"EA Calvier","year":"2016","unstructured":"Calvier EA, Krekels EH, Valitalo PA, et al. Allometric scaling of clearance in paediatric patients: when does the magic of 0.75 fade? Clin Pharmacokinet. 2016. doi: 10.1007\/s40262-016-0436-x . [Epub ahead of print].","journal-title":"Clin Pharmacokinet."},{"key":"512_CR28","doi-asserted-by":"publisher","unstructured":"Liu T, Ghafoori P, Gobburu JV. Allometry is a reasonable choice in pediatric drug development. J Clin Pharmacol. doi: 10.1002\/jcph.831 . [Epub ahead of print].","DOI":"10.1002\/jcph.831"},{"issue":"8","key":"512_CR29","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40262-013-0065-6","volume":"52","author":"AN Edginton","year":"2013","unstructured":"Edginton AN, Shah B, Sevestre M, Momper JD. The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years. Clin Pharmacokinet. 2013;52(8):693\u2013703.","journal-title":"Clin Pharmacokinet"},{"issue":"7289","key":"512_CR30","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nature08920","volume":"464","author":"T Kolokotrones","year":"2010","unstructured":"Kolokotrones T, Van S, Deeds EJ, Fontana W. Curvature in metabolic scaling. Nature. 2010;464(7289):753\u20136.","journal-title":"Nature"},{"issue":"4","key":"512_CR31","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s11095-010-0333-1","volume":"28","author":"EH Krekels","year":"2011","unstructured":"Krekels EH, van Hasselt JG, Tibboel D, et al. Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. Pharm Res. 2011;28(4):797\u2013811.","journal-title":"Pharm Res"},{"issue":"10","key":"512_CR32","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1002\/jps.21682","volume":"98","author":"I Mahmood","year":"2009","unstructured":"Mahmood I. Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. J Pharm Sci. 2009;98(10):3850\u201361.","journal-title":"J Pharm Sci"},{"issue":"5","key":"512_CR33","doi-asserted-by":"crossref","first-page":"e1242","DOI":"10.1542\/peds.2010-3487","volume":"128","author":"J Dunne","year":"2011","unstructured":"Dunne J, Rodriguez WJ, Murphy MD, et al. Extrapolation of adult data and other data in pediatric drug-development programs. Pediatrics. 2011;128(5):e1242\u20139.","journal-title":"Pediatrics"},{"issue":"1","key":"512_CR34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cmpb.2012.08.009","volume":"109","author":"TT Bergsma","year":"2013","unstructured":"Bergsma TT, Knebel W, Fisher J, et al. Facilitating pharmacometric workflow with the metrumrg package for R. Comput Methods Programs Biomed. 2013;109(1):77\u201385.","journal-title":"Comput Methods Programs Biomed"},{"key":"512_CR35","volume-title":"WinPOPT (version 1.2) user guide","author":"S Duffull","year":"2008","unstructured":"Duffull S, Denman N, Eccleston J, Kimko H. WinPOPT (version 1.2) user guide. Dunedin: School of Pharmacy, University of Otago; 2008."},{"issue":"10","key":"512_CR36","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1177\/0091270011422812","volume":"52","author":"Y Wang","year":"2012","unstructured":"Wang Y, Jadhav PR, Lala M, Gobburu JV. Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies. J Clin Pharmacol. 2012;52(10):1601\u20136.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"512_CR37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/ijo.2012.55","volume":"37","author":"E D\u2019Hondt","year":"2013","unstructured":"D\u2019Hondt E, Deforche B, Gentier I, et al. A longitudinal analysis of gross motor coordination in overweight and obese children versus normal-weight peers. Int J Obes (Lond). 2013;37(1):61\u20137.","journal-title":"Int J Obes (Lond)"},{"issue":"3","key":"512_CR38","doi-asserted-by":"crossref","first-page":"315","DOI":"10.5498\/wjp.v5.i3.315","volume":"5","author":"TV Damme","year":"2015","unstructured":"Damme TV, Simons J, Sabbe B, van West D. Motor abilities of children and adolescents with a psychiatric condition: a systematic literature review. World J Psychiatry. 2015;5(3):315\u201329.","journal-title":"World J Psychiatry"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-017-0512-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-017-0512-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-017-0512-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T14:27:03Z","timestamp":1568816823000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-017-0512-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,15]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["512"],"URL":"https:\/\/doi.org\/10.1007\/s40262-017-0512-x","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,15]]}}}